0001415889-24-002379.txt : 20240202
0001415889-24-002379.hdr.sgml : 20240202
20240202175307
ACCESSION NUMBER: 0001415889-24-002379
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240201
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hannah Brendan
CENTRAL INDEX KEY: 0001929422
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38890
FILM NUMBER: 24593138
MAIL ADDRESS:
STREET 1: 269 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Quince Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662774
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 901024039
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 273
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-910-5717
MAIL ADDRESS:
STREET 1: 611 GATEWAY BLVD., SUITE 273
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cortexyme, Inc.
DATE OF NAME CHANGE: 20160104
4
1
form4-02022024_100258.xml
X0508
4
2024-02-01
0001662774
Quince Therapeutics, Inc.
QNCX
0001929422
Hannah Brendan
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD, SUITE 273
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
CHIEF BUSINESS OFFICER AND COO
0
Employee Stock Option (right to buy)
1.31
2024-02-01
4
A
0
600000
0
A
2034-01-31
Common Stock
600000
600000
D
The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2024, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.
/s/ Brendan Hannah
2024-02-01